Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction
US8518401B1 · kind B1 · utility
1Cited by
10References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2005 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Jun 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.